Entrada Therapeutics, Inc. (TRDA)

Nasdaq Pharmaceutical Pharmaceutical Preparations SIC: 2834
D
Pipeline Grade

Financial Position (from SEC Filings)

$79.7M
Cash & Equivalents
$41.7M
Quarterly Burn Rate
6 mo
Est. Cash Runway
$257M
Market Cap

Estimated from most recent SEC quarterly filing. View SEC filings

Drug Pipeline (0 Assets)

No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.

Upcoming Catalysts

No upcoming catalysts detected for this company.

Active Clinical Trials (2)

NCT #TitlePhaseStatusEnrollment
NCT07037862 A Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping to Evaluate the Safety and Efficac... PHASE2 Recruiting 24
NCT07038824 A Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping to Evaluate the Safety and Efficac... PHASE2 Recruiting 24

Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.

More Analysis

AI Stock Score

SEC EDGAR fundamental analysis with Claude AI & ChatGPT ratings for TRDA.

SEC EDGAR Filings

All SEC filings for Entrada Therapeutics, Inc. on EDGAR.

Full Calendar

View all upcoming FDA catalysts across all biotech companies.